Biotechnology company Amphista Therapeutics has announced its nomination of AMX-883 as its first clinical development candidate for the treatment of acute myeloid leukaemia (AML). 

AMX-883 is a potent, selective and orally bioavailable degrader of BRD9. Leveraging Amphista’s Eclipsys platform and proprietary Targeted Glue technology, AMX-883 induces the degradation of BRD9 via induction of the E3 ligase DCAF16, a completely novel mechanism, distinct from CRBN and VHL-based technologies. 

AMX-883 can induce almost complete degradation of BRD9 within just two hours of treatment, whilst retaining exquisite selectivity over all other bromodomain containing proteins, and beyond, as illustrated by global proteomics. This profile translates into robust in vivo efficacy, including in disseminated patient derived xenograft models. 

“Nominating AMX-883 as our first clinical candidate, marking the first time a BRD9 degrader has been developed in AML, is a key milestone for Amphista and the TPD field,” said Martin Pass, Chief Development Officer at Amphista.  

“Our preclinical data package underlines the fundamental role BRD9 plays in the pathogenesis of AML. AMX-883 has the potential to transform the treatment paradigm for this terrible disease, where five-year survival rates remain at just 33% and is the cause of death for an estimated 130,000 patients globally each year.”  

“As a broad-acting, pro-differentiation agent, AMX-883 has the potential to treat AML in a karyotype-independent way, bringing benefit to a larger patient population than current treatments.” 

The role of BRD9 in AML

Acute myeloid leukaemia (AML) is one of the most aggressive blood cancers. Despite the availability of anti-proliferative treatments, patient survival rates remain low. The disease is characterised by a differentiation block which prevents myeloid cell maturation and results in an accumulation of immature cells/AML blasts. There is an urgent need for broader-acting treatments that can benefit patients regardless of their genetic profile. 

BRD9 is a subunit of the non-canonical BAF complex where it plays a key structural and functional role, being linked to regulation of chromatin structure and maintaining genomic stability in AML. Degradation of BRD9 releases the differentiation block and leads to the differentiation and death of AML blasts. 

The nomination of AMX-883 by Amphista follows the company’s announcement in May 2024, unveiling its discovery of a new differentiated mechanism of action for BRD9 degradation. This year, the company also unveiled a new mechanism of action for TEAD degradation via FBXO22, and for SMARCA2 degradation via induction E3 ligase DCAF16. 

Amphista plans to initiate its first clinical trial with AMX-833 in the second half of 2026. 

 

Bruno Quinney, Content Team, DDW